Immuneering’s (IMRX) “Buy” Rating Reiterated at Chardan Capital

Chardan Capital restated their buy rating on shares of Immuneering (NASDAQ:IMRX) in a research note issued to investors on Thursday morning,Benzinga reports. The brokerage currently has a $13.00 target price on the stock.

IMRX has been the subject of a number of other reports. Mizuho upped their target price on shares of Immuneering from $8.00 to $10.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 18th. Needham & Company LLC restated a “buy” rating and set a $9.00 price objective on shares of Immuneering in a research note on Wednesday, June 18th. Finally, Oppenheimer reduced their price objective on shares of Immuneering from $25.00 to $21.00 and set an “outperform” rating for the company in a research note on Wednesday, May 7th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Based on data from MarketBeat, Immuneering presently has a consensus rating of “Moderate Buy” and a consensus target price of $13.25.

Immuneering Trading Up 23.7%

Shares of NASDAQ IMRX opened at $3.76 on Thursday. The firm has a market cap of $136.56 million, a PE ratio of -1.99 and a beta of 0.37. Immuneering has a 1-year low of $1.00 and a 1-year high of $4.69. The company has a fifty day moving average price of $3.39 and a 200 day moving average price of $2.20.

Immuneering (NASDAQ:IMRX) last announced its earnings results on Wednesday, August 13th. The company reported ($0.40) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.40). Equities research analysts forecast that Immuneering will post -1.86 EPS for the current year.

Insider Transactions at Immuneering

In other news, Director Thomas J. Schall bought 40,485 shares of the business’s stock in a transaction that occurred on Tuesday, June 17th. The stock was acquired at an average cost of $2.21 per share, for a total transaction of $89,471.85. Following the purchase, the director owned 43,385 shares of the company’s stock, valued at approximately $95,880.85. This trade represents a 1,396.03% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Benjamin J. Zeskind bought 21,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 18th. The stock was purchased at an average price of $2.39 per share, with a total value of $50,190.00. Following the completion of the purchase, the chief executive officer directly owned 2,302,852 shares in the company, valued at $5,503,816.28. The trade was a 0.92% increase in their position. The disclosure for this purchase can be found here. Insiders acquired a total of 127,507 shares of company stock worth $334,318 in the last three months. Insiders own 22.90% of the company’s stock.

Institutional Investors Weigh In On Immuneering

Several hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC lifted its stake in Immuneering by 2.0% in the 2nd quarter. Geode Capital Management LLC now owns 230,275 shares of the company’s stock valued at $776,000 after purchasing an additional 4,458 shares during the last quarter. Southport Management L.L.C. lifted its stake in Immuneering by 4.9% in the 4th quarter. Southport Management L.L.C. now owns 215,000 shares of the company’s stock valued at $473,000 after purchasing an additional 10,000 shares during the last quarter. Rockefeller Capital Management L.P. acquired a new stake in Immuneering in the 4th quarter valued at about $390,000. Bridgeway Capital Management LLC lifted its stake in Immuneering by 57.9% in the 2nd quarter. Bridgeway Capital Management LLC now owns 95,449 shares of the company’s stock valued at $322,000 after purchasing an additional 35,000 shares during the last quarter. Finally, HighTower Advisors LLC lifted its stake in Immuneering by 17.7% in the 1st quarter. HighTower Advisors LLC now owns 83,960 shares of the company’s stock valued at $128,000 after purchasing an additional 12,600 shares during the last quarter. 67.65% of the stock is currently owned by institutional investors and hedge funds.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.